Abstract: Providing user interaction guidance for services and associated applications may become more difficult as their variety and depth increases. Embodiments are directed to managing activation of and providing guidance on how to use a hosted service. For example, an initial configuration of a user interface (UI) of the hosted service that includes at least one element to highlight functionality may be provided for display. An initial action may be received from a user associated with the functionality, the initial action may be performed, and the UI may be updated to reflect the performed initial action. The initial action may be an activation action or upload action, for example. Additionally, a teaching UI element with a celebratory message to highlight the performed initial action and to provide additional information may be provided for display and rendered at a proximate position to a representation of the performed initial action.

Abstract: A pubic catheter apparatus (20) for storing a urinary catheter and drawing fluid from a bladder comprises a sanitation unit (66) defining a sanitation chamber (68) for impermeably sealing a fluid outlet (42) of the catheter from the environment when the fluid outlet (42) is disposed in the sanitation chamber (68). A support (54, 72) having a retained condition for connecting and holding the sanitation unit (66) adjacent to the body of the human and a release condition for releasing and removing the sanitation unit (66) from the body of the human. The support (54, 72) can include a belt (54) and a pouch (48) disposed thereon for surrounding and storing the sanitation unit (66), and connectors (72) in the pouch (48) having the retained condition for holding the sanitation unit (66) in the pouch (48) and the release condition for removing the sanitation unit (66) from the pouch (48).

Abstract: Soft absorbent sheets, structuring fabrics for producing soft absorbent sheets, and methods of making soft absorbent sheets. The soft absorbent sheets have a plurality of domed regions or projected regions extending from a surface of the sheets, and connecting regions form a network between domed regions. The domed and projected regions include indented bars that extend across the domed and projected regions in a substantially cross machine direction of the absorbent sheets. The absorbent sheets can be formed by structuring fabrics that have long warp yarn knuckles.

Abstract: The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Abstract: Soft absorbent sheets, structuring fabrics for producing soft absorbent sheets, and methods of making soft absorbent sheets. The soft absorbent sheets have a plurality of domed regions or projected regions extending from a surface of the sheets, and connecting regions form a network between domed regions. The domed and projected regions include indented bars that extend across the domed and projected regions in a substantially cross machine direction of the absorbent sheets. The absorbent sheets can be formed by structuring fabrics that have long warp yarn knuckles.

Abstract: Apparatus for safely and accurately positioning the fingertip of a physician (or technician) performing a biopsy procedure, e.g., to excise a core tissue samples of the male prostate or other internal organs, to avoid injury (e.g., a needle stick) from the sharpened distal end of a biopsy needle assembly. Such apparatus comprises an open tubular member defining an elongated passageway through which a biopsy needle assembly, when actuated, can be made to pass and to extend a predetermined distance along an external path in order to effect the core sampling of a biological mass of interest. The tubular housing supports a safety flange at its distal end, such flange having a flat surface adapted to be engaged by the fingertip of the physician prior to actuation of the biopsy needle assembly.

Abstract: Current systems for data authentication, such as in the course of financial transactions to comply with anti-money laundering and know-your-customer legislation, are burdensome and inefficient for banks and their clients. A platform of some embodiments provides a system for utilizing distributed ledger technologies, such as a blockchain data structure residing on a distributed ledger. A client may use this blockchain data structure to register the client's personal information in a data object that then may be routed to specific identified trusted individuals who verify that the information in the data object is correct. Once verification is complete, the client or other trusted individuals may use the data object as necessary to register the client for various programs or services, such as additional bank services.

Abstract: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.

Abstract: A method of making a fabric-creped absorbent cellulosic sheet. The method includes compactively dewatering a papermaking furnish to form a web, creping the web under pressure in a creping nip between a transfer surface and a structuring fabric, the structuring fabric including knuckles formed on warp yarns of the structuring fabric, with the knuckles being positioned along lines that are angled relative to the machine direction of the fabric. The angle of lines relative to the machine direction is between about 10° and about 30°. The method also includes drying the web to form the absorbent cellulosic sheet.

Abstract: Soft absorbent sheets, structuring fabrics for producing soft absorbent sheets, and methods of making soft absorbent sheets. The soft absorbent sheets have a plurality of projected regions and connecting regions that connect the projected regions. The projected regions include folds that are curved relative to a machine direction of the absorbent sheet, with ends of the curved folds being on opposite sides of the projected regions, and with apexes of the curved folds being positioned downstream in the machine direction of the absorbent sheet. The absorbent sheets can be formed by structuring fabrics that have angled lines of warp yarn knuckles.

Abstract: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.

Abstract: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.

Abstract: Soft absorbent sheets, structuring fabrics for producing soft absorbent sheets, and methods of making soft absorbent sheets. The soft absorbent sheets have a plurality of domed regions or projected regions extending from a surface of the sheets, and connecting regions form a network between domed regions. The domed and projected regions include indented bars that extend across the domed and projected regions in a substantially cross machine direction of the absorbent sheets. The absorbent sheets can be formed by structuring fabrics that have long warp yarn knuckles.

Abstract: Providing user interaction guidance for services and associated applications may become more difficult as their variety and depth increases. Embodiments are directed to managing activation of and providing guidance on how to use a hosted service. For example, an initial configuration of a user interface (UI) of the hosted service that includes at least one element to highlight functionality may be provided for display. An initial action may be received from a user associated with the functionality, the initial action may be performed, and the UI may be updated to reflect the performed initial action. The initial action may be an activation action or upload action, for example. Additionally, a teaching UI element with a celebratory message to highlight the performed initial action and to provide additional information may be provided for display and rendered at a proximate position to a representation of the performed initial action.

Abstract: Soft absorbent sheets, structuring fabrics for producing soft absorbent sheets, and methods of making soft absorbent sheets. The soft absorbent sheets have a plurality of domed regions or projected regions extending from a surface of the sheets, and connecting regions form a network between domed regions. The domed and projected regions include indented bars that extend across the domed and projected regions in a substantially cross machine direction of the absorbent sheets. The absorbent sheets can be formed by structuring fabrics that have long warp yarn knuckles.

Abstract: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.

Abstract: The present invention relates to novel substituted bridged urea analog compounds of Formula (I) or pharmaceutically acceptable salts thereof, corresponding pharmaceutical compositions, processes for making and use of such compounds, alone or in combination with other therapeutic agents, as Sirtuin Modulators useful for increasing lifespan of a cell, and for use in treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity.

Abstract: The present invention relates to novel substituted bridged urea compounds, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Abstract: The present invention relates to novel substituted bridged urea compounds of Formula (I): or a pharmaceutically acceptable salt thereof, corresponding related analogs, pharmaceutical compositions and methods of use thereof. Sirtuin-modulating compounds of the present invention may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders, which include, but are not limited to, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benefit from increased mitochondrial activity. The present invention also related to compositions comprising a sirtuin-modulating compound in combination with another therapeutic agent.

Abstract: This invention relates to novel compounds according to Formula (III)(a) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), and to pharmaceutical compositions containing them.